Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway

International Journal of Oncology
Jie LiXianbao Zhan

Abstract

Drug resistance is a major cause of cancer‑associated mortality. Epirubicin‑based chemotherapy initially benefits patients with metastatic or advanced gastric cancer; however, tumor recurrence can occur following several courses of treatment. Mitochondrial ribosomal protein L33 (MRPL33)‑long (L) and MRPL33‑short (S), isoforms of MRPL33 that arise from AS, have been reported to regulate cell growth and apoptosis in cancer; however, few studies have evaluated the roles of MRPL33‑L and MRPL33‑S in gastric cancer. In the present study, MRPL33‑L was demonstrated to be significantly more abundant in gastric tumor tissues than the MRPL33‑S isoform. MRPL33‑S promoted chemosensitivity to epirubicin in gastric cancer as demonstrated by a chemoresponse assay; chemosensitivity was suppressed in response to MRPL33‑L. Gene microarray analysis was performed to investigate the underlying mechanisms. Bioinformatic analysis revealed that overexpression of MRPL33‑L and MRPL33‑S served critical roles in transcription, signal transduction and apoptosis. In particular, the phosphoinositide 3‑kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling pathway was markedly regulated. A total of 36 target genes, including PIK3 regulatory subunit α, AKT2,...Continue Reading

References

Jan 10, 2004·Journal of Neurochemistry·Gautam N Bijur, Richard S Jope
Oct 7, 2011·Bioinformatics·Eleanor A HoweJohn Quackenbush
Jan 21, 2012·Nature Reviews. Drug Discovery·Ryszard KoleSidney Altman
Nov 6, 2012·Nature Reviews. Drug Discovery·Sophie BonnalJuan Valcárcel
Mar 5, 2013·Current Biology : CB·Uwe RichterBrendan J Battersby
Apr 23, 2013·Cellular Signalling·Ekta AgarwalSanjib Chowdhury
Dec 18, 2013·Oncogene·S Oltean, D O Bates
Oct 11, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Tianyu LiYu Ye
Dec 17, 2014·Expert Opinion on Drug Metabolism & Toxicology·Anna WojtuszkiewiczJacqueline Cloos
Jan 1, 2015·ELife·Igor VivancoIngo K Mellinghoff
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jun 16, 2015·Acta Pharmacologica Sinica·Kai-qin LeLiang-cheng Li
Dec 21, 2016·International Journal of Cancer. Journal International Du Cancer·Lindsay D SmithDiana Baralle
Mar 16, 2017·EMBO Molecular Medicine·Caroline GodfreyVirginia Arechavala-Gomeza
Apr 27, 2017·Seminars in Cancer Biology·Hyun-Jung KimAntoni Barrientos
Jun 20, 2017·Current Problems in Cancer·Beata Polkowska-PruszyńskaWojciech P Polkowski
Oct 29, 2017·Current Opinion in Genetics & Development·Zahava Siegfried, Rotem Karni
Mar 23, 2018·Human Molecular Genetics·Anlu ChenDavid A Buchner
Apr 28, 2018·Nature Communications·Gray R AndersonKris C Wood

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Protein Assay

Software Mentioned

MultiExperiment Viewer
Cytoscape
Affymetrix GeneChip Command Console
SPSS
ImageJ
GeneSpring

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.